Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Why Is Intuitive Surgical Stock Falling in Pre-Market Trading? - Yahoo Finance

Analyst upgrade Earnings report Legal settlement AI-generated analysis

πŸ“‰ ISRG shares declined 7.5% to $404.99 in pre-market trading following Q3 2026 earnings despite beating adjusted EPS and revenue estimates.

βš–οΈ The company recorded a $450 million pre-tax charge for the settlement of the da Vinci Surgical Robot Antitrust Litigation, reducing GAAP net income to $1.49 per share.

πŸ“‰ Management plans to reduce pricing on surgical instruments and accessories by 3% to 5%, which is expected to lower revenue per procedure once fully implemented.

🌍 International da Vinci procedure volumes increased by 20% year-over-year, outpacing the 10% growth seen in the US market.

πŸ“Š Analysts maintained positive ratings with JPMorgan raising its price target to $475 and Barclays increasing it to $500 despite the pricing adjustments.

πŸ” Investors are assessing whether higher procedure volumes can offset the revenue impact of the planned pricing reductions on recurring revenue streams.

πŸ“ˆ Adjusted EPS of $3.00 exceeded the consensus estimate of $2.65, while total revenue reached $3.05 billion against expectations of $2.91 billion.

Bullish Signals
  • Intuitive Surgical reported third-quarter non-GAAP earnings of $3.00 per share, surpassing the analyst consensus estimate of $2.65.
  • Revenue reached $3.05 billion, exceeding market expectations of $2.91 billion.
  • International da Vinci procedure volumes increased by 20% year-over-year, indicating strong growth outside the United States.
  • US da Vinci procedures grew by 10% year-on-year during the third quarter.
  • Major investment banks maintained positive ratings with JPMorgan raising its price target to $475 and Barclays increasing it to $500.
Risk Factors
  • A $450 million pre-tax charge associated with the settlement of the class-action antitrust litigation reduced GAAP net income significantly.
  • The domestic US procedure growth rate of 10% was among the company's lowest readings in recent years, indicating slowing momentum in its largest market.
Full Analysis
Intuitive Surgical (ISRG) shares fell 7.5% in pre-market trading following its third-quarter 2026 earnings report, despite adjusted EPS of $3.00 and revenue of $3.05 billion both beating analyst estimates. The stock decline was primarily driven by a $450 million pre-tax charge related to the settlement of the da Vinci Surgical Robot Antitrust Litigation, which reduced GAAP net income to $1.49 per share compared to $1.95 in the prior-year period. Management confirmed plans to reduce pricing for certain surgical instruments and accessories by approximately 3% to 5% on a constant-mix basis once fully implemented. This strategic adjustment is expected to lower revenue per procedure, prompting investor scrutiny regarding its impact on the company's recurring revenue stream from installed robotic systems. The move aims to potentially stimulate demand, though the net effect on overall growth remains dependent on future procedure volumes and operating costs. Operational performance showed a divergence between domestic and international markets, with US da Vinci procedures rising 10% year-over-year while international volumes surged 20%. Analysts from major banks including JPMorgan, Raymond James, and Barclays maintained positive ratings but adjusted price targets to reflect the pricing changes and legal settlement. The market is closely watching whether higher procedure volumes, particularly in international markets, can offset the revenue headwinds from lower instrument pricing as the company heads into 2027.